Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-17
2010-10-05
Haddad, Maher M (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388220
Reexamination Certificate
active
07807794
ABSTRACT:
The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 6291196 (2001-09-01), Vielkind
patent: 2003/0109435 (2003-06-01), Prenner et al.
patent: 2004/0162413 (2004-08-01), Watkins et al.
patent: 2008/0181888 (2008-07-01), Ambrose et al.
patent: 0759302 (2000-08-01), None
patent: WO2006/022682 (2006-03-01), None
Ho et al. Modulation of in vivo migratory function of alpha 2 beta 1 integrin in mouse liver. Mol Biol Cell. Oct. 1997;8(10):1863-75.
Lerner R. Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature 1982; 299:592-596.
Fundamental Immunology, William E. Paul, ed., 3rd Ed., pp. 292-295, 1993.
Van Regenmortel MHV. Mapping Epitope Structure and Activity: From One-Dimensional Prediction to Four-Dimensional Description of Antigenic Specificity Methods. 9(3):465-72, 1996.
Casset et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational desig. Biochem Biophys Res Commun. Jul. 18, 2003;307(1):198-205.
MacCallum et al Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. Oct. 11, 1996;262(5):732-45.
Bendig M. M. Humanization of Rodent Monoclonal Antibodies ,by CDR Grafting. Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.
Colman PM. Effects of amino acid sequence changes on antibody-antigen interactions. Res Immunol. 145(1):33-36, 1994.
Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Estavillo, D. et al., “Functional Analysis of a Recombinant Glycoprotein la/lla (Integrin a2b1) I Domain That Inhibits Platelet Adhesion to Collagen and Endothelial Matrix under Flow Conditions,” The Journal of Biological Chemistry, vol. 274, pp. 35921-35926,1999.
Schoolrneester, A. et al., “Monoclonal antibody IAC-1 is specific for activated a2Pi and binds to amino acids 199 to 201 of the integrin a2 I-domain,” Hemostasis, Thrombosis, and Vascular Biology, vol. 104, pp. 390-396, 2004.
Smith, C. et al., “Mapping the Collagen-binding Site in the I Domain of the Glycoprotein Ia/IIa (Integrin a2b1)*,” The Journal of Biological Chemistry, vol. 275, pp. 4206-4209, 2000.
Tuckwell, D. et al., “Monoclonal antibodies identify residues 199-216 of the integrin a2 vWFA domain as a functionally important region within a2b1,” Biochem. J., vol. 350, pp. 485-493, 2000.
Al-Lazikani et al, J. Mol. Biol., “Standard conformations for the canonical structures of immunoglobulins.” 273 (4):927-48 (1997).
Andreasen S.O. et al., J. Immunol., Expression and functional importance of collagen-binding integrins, alpha 1 beta 1 and alpha 2 beta 1, on virus-activated T cells. 171:2804-2811 (2003).
Aquilina A, et al., Eur. J. Biochem, “A novel gain-of-function mutation of the integrin alpha2 VWFA domain.” 269 (4):1136-44 (2002).
Argraves, W.S, J. Cell. Biol., “Amino acid sequence of the human fibronectin receptor.” 105(3):1183-90 (1987).
Bahou W.F., et al., Blood. “The VLA-2 (alpha 2 beta 1) I domain functions as a ligand-specific recognition sequence for endothelial cell attachment and spreading: molecular and functional characterization.” 84(11):3734-3741 (1994).
Bergelson J.M., et al., Cell Adhes. Commun. “The I domain is essential for echovirus 1 interaction with VLA-2.” 2 (5):455-64 (1994).
Bhatt, D.L. and Topol, E.J., Nat. Rev. Drug Discov., “Scientific and therapeutic advances in antiplatelet therapy.” 2 (1):15-28 (2003).
Champe, M., et al., J. Biol. Chem., Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a. 270(3):1388-94 (1995).
Chan, et. al., J. Immunol., “T cell receptor-dependent, antigen-specific stimulation of a murine T cell clone induces a transient, VLA protein-mediated binding to extracellular matrix.” 147:398-404 (1991).
Chen, J., et al., E. pub Jan. 11, 2002; Am. J. Pathol., “The •2Integrin Subunit-Deficient Mouse: A Multifaceted Phenotype Including Defects of Branching Morphogenesis and Hemostasis” 161(1):337-344 (2002).
Cheng, Y. and Prusoff, W.H., Biochem. Pharmacol., “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.” 22(23):3099-108 (1973).
Clackson, T., et al., Nature, “Making antibody fragments using phage display libraries.” 352:624-628 (1991).
Colombatti, A. and Bonaldo, P., Blood, “The superfamily of proteins with von Willebrand factor type A-like domains: one theme common to components of extracellular matrix, hemostasis, cellular adhesion, and defense mechanisms” 77(11):2305-15 (1991).
Cunningham, B.C. and Wells, J.A., Science, “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis” 244: 1081-1085 (1989).
De Fougerolles, A., et al., J. Clin. Invest, Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. 105:721-720 (2000).
Kamata, T., et. al., J Biol.Chem., “Integrin 2 1. Critical Role of Conserved Residues in the Metal Ion-Dependent Adhesion Site (MIDAS) Region” 274 (v274 = 1999), 32108-32111 (1999).
Dickeson, S.K., et al., Cell Adhesion and Communication, “Binding of the alpha 2 integrin I domain to extracellular matrix ligands: structural and mechanistic differences between collagen and laminin binding” 5: 273-281 (1998).
Dickeson, S.K., et al., J Biol. Chem., “Contributions of the I and EF hand domains to the divalent cation-dependent collagen binding activity of the alpha2beta1 integrin.” 272: 7661-7668 (1997).
Dustin, M.L. and de Fougerolles, A., Curr Opin Immunol, “Reprogramming T cells: the role of extracellular matrix in coordination of T cell activation and migration.” 13:286-290 (2001).
Eble, J.A., Curr. Pharm. Des., “Collagen-binding integrins as pharmaceutical targets.” 11(7):867-880 (2005).
Edelson, B.T., et al., Blood, “Mast cell-mediated inflammatory responses require the alpha 2 beta 1 integrin.” 103 (6):2214-2220 (2004).
Edelson, B.T., et al., Blood, “Novel collectin/C1q receptor mediates mast cell activation and innate immunity”. 107(1): 143-50 (2006).
Emsley, J., et al., Cell, “Structural basis of collagen recognition by integrin alpha2beta1.” 101(1):47-56 (2000).
Emsley, J., et al., J. Biol. Chem., “Crystal structure of the I domain from integrin alpha2beta1” 272(45):28512 (1997).
Feuston, B.P., et al., J. Med. Chem., “Molecular model of the alpha(IIb)beta(3) integrin” 46:5316-5325 (2003).
Foote, J. and Winter, G., J. Mol. Biol., “Antibody framework residues affecting the conformation of the hypervariable loops.” 224: 487-99 (1992).
Gadek, T.R., et al., Science, Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. 295(5557):1086-9 (2002).
Giltay, J.C., et al., Blood, “Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2” 73(5):1235-41 (1989).
Gruner, S., et al., Blood, “Multiple integrin-ligand interactions synergize in shear-resistant platelet adhesion at sites of arterial injury in vivo” 102:4021-4027 (2003).
Gurrath, M., et al., Eur. J. Bioch
Bernard Mark
Lazarides Elias
Woods Catherine Mary
Glenmark Pharmaceuticals S.A.
Haddad Maher M
K&L Gates LLP
LandOfFree
Anti-α2 integrin antibodies and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-α2 integrin antibodies and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-α2 integrin antibodies and their uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152147